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Introduction
Miscarriage, defined as a spontaneous loss of the conceptus before 20 weeks' gestation, is clinically detected in approximately 10-15 % of pregnancies and recurs in 5% of subsequent pregnancies. 1 Recurrent miscarriage is often defined by three or more consecutive losses and affects one to two percent of couples trying to have children. 2 However, many experts accept two consecutive losses as sufficient for the diagnosis of recurrent miscarriage because the recurrence rate is close to that after three losses 3 . In addition, the prevalence of abnormal results for evidence-based diagnostic tests does not differ among women after 2 rather than 3 losses. 4 Moreover, distressed women are often referred for care after two losses rather than three. Causes and recurrence rates differ according to the gestational age at miscarriage. Most women have recurrent early loss with a failure of development before 10 weeks, although clinical symptoms most often occur after 10 weeks' gestation. Therefore, the traditional grouping of all pregnancy losses before 20 weeks has been revised. 5 Standard investigations fail to reveal any apparent cause in more than 50% of the couples. 1, 2 On the basis of a parallel drawn with the antiphospholipid syndrome, hypotheses on thrombotic mechanisms were raised in unexplained pregnancy loss. An association with some inherited thrombophilias was suggested. 6, 7, 8 At the time our study was designed, a randomized open-label trial suggested a strong benefit of low-molecular-weight heparin (LMWH) versus aspirin to improve the live-birth rate in women with at least one previous loss after 10 weeks' gestation and an inherited thrombophilia. 9 This led to extensive use of LMWH as the standard of care in thrombophilic women with recurrent miscarriage. Moreover, despite the lack of such a recommendation in evidence-based guidelines, it had become common practice in many centers to provide
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Although our goal was to evaluate the efficacy of LMWH in women with recurrent miscarriage regardless of the presence of a known thrombophilia, such a trial would have been deemed unethical in thrombophilic women at that time. Moreover, since nonpharmacological interventions such as psychological support potentially improve the birth rate among women with recurrent miscarriage, 2 we strongly felt that a double-blind randomized trial was particularly required to avoid bias. 10 Therefore, in 2006, we designed the PREFIX (Prevention of Unexplained Recurrent
Abortion by Enoxaparin) study, a randomized double-blind placebo-controlled multi-center trial, to investigate whether LMWH would improve the live-birth rate among nonthrombophilic women.
Methods

Ethics Statement and Trial Registration
The study protocol was approved by the local Ethics Committee, the CPP of Brest University Since June 2006, no changes were made to the study outcomes, enrolment criteria, study design or methodology used.
All patients provided written informed consent.
Study population
Between April 4, 2007 and October 31, 2012, women were enrolled in 13 French hospital centers (Bordeaux, Brest, Caen, Dijon, La Réunion, Lille, Lorient, Marseille, Montpellier, Paris, Pau, Rouen, Saint-Etienne). Prior to initiation, the study was advertised to all obstetricians working in each participating center's catchment area, who were asked to refer potentially eligible women.
Inclusion criteria were pregnant woman, aged 18-45 years, with a history of unexplained recurrent miscarriage. The current pregnancy had to be confirmed by a clinician. Unexplained recurrent miscarriage was diagnosed in cases of normal karyotypes of both partners, the absence of any anatomical abnormality likely to be responsible for miscarriage, 
Study Design
Women were included very early in pregnancy, ideally before 5 weeks' gestation, after a positive pregnancy test. At the first visit, after confirming eligibility and obtaining consent, women were randomized using a central web-based randomization system (ClinInfo inc., Lyon, France), and received education for self-injections. Blocked randomization (allocation ratio of 1:1, block size of 6) was stratified according to study center and to three levels of disease severity, based on combination of woman's age and the number of previous miscarriages. This was done in line with a previous longitudinal study on prediction of success rates of subsequent pregnancy (Table 1) . 12 Women were randomly assigned to receive enoxaparin 40 mg daily or placebo (saline solution). Enoxaparin and placebo were purchased from Sanofi-Aventis (branch ROVI for Placebo-Enoxaparin syringes, Madrid, Spain), then they were packaged and labelled by the pharmacy's clinical trial unit at Brest university hospital. Enoxaparin and placebo were contained in identical syringes and packed in identical sachets. Treatment was administered subcutaneously once a day, initiated from the inclusion visit (or within 24 hours) and continued by self injection until 35 weeks' gestation.
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Patients, doctors, and trial nurses were all unaware of the study-group assignments.
Women also received standard care and pregnancy monitoring, including fetal ultrasounds, by their own obstetrician, throughout pregnancy. All women were advised to take folic acid supplementation.
Outcome Measures
The primary outcome measure was the rate of live and viable births. In case of preterm and or low birth weight, we defined the viability by the decision to transfer the new-born to a neonatal intensive care unit.
Secondary outcomes included rates of miscarriage, rates of obstetric complications (intrauterine fetal death after 20 weeks'gestation, preeclampsia, birth of a small for gestational age child, placental abruption, and premature delivery), rates of maternal thrombocytopenia (defined as a platelet count <0.6x baseline platelet count or as a platelet count <100,000 per cubic millimeter), bleeding episodes and skin reactions.
All information as regards the infant and delivery were collected during the last visit, most often performed around two months after delivery. Obstetrical and pediatric medical reports were retrieved.
Statistical analysis
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Baseline characteristics of the study population were expressed as means and standard deviation, or number of patients and proportions, as appropriate. The primary outcome and the rates of different classifications of pregnancy loss were assessed in all women, according to the intention-to-treat principle. Differences in dichotomous outcomes among the two study groups were analyzed with the use of the chi-square test or Fisher's exact test as appropriate.
Differences in live-birth rates were expressed as absolute differences and relative risks, with associated 95% confidence intervals, with the placebo group as the reference. A t-test was used to compare continuous outcome measures.
The incidences of preeclampsia, placental abruption, preterm delivery, small size for gestational age, were calculated for women who had an ongoing pregnancy beyond 20 weeks' gestation. Adverse maternal events and congenital abnormalities were collected for all patients.
A per-protocol analysis was also planned, taking into account actual exposure to the assigned study drug. We restricted the analysis to women who were exposed for at least 7 days, and until loss or beyond 12 weeks' gestation. Additionally, the study drug had to be administered early enough, i.e. before 6 weeks' gestation, or at least one week before the most advanced term reached during previous pregnancies.
Subgroup analyses were conducted in the following sub-groups: maternal age (<35 or ≥ 35), number of previous miscarriages (2 or ≥ 3), strata of randomization, parity (presence or absence of previous live birth), history of late fetal death whose causes and recurrence rates may differ (presence or absence of previous fetal death after 10 weeks' gestation) 3 . Relative risks for a live birth with enoxaparin compared to placebo were calculated for the separate subgroups. To compare the relative risks among subgroups, we used a test of interaction according to the method described by Atman DG. 13 A P value of less than 0.05 was considered to indicate statistical significance.
Luc de Saint Martin analyzed the data and all authors had access to primary clinical trial data.
Sample size
In a previous longitudinal study of pregnancy outcome following idiopathic recurrent miscarriage in 325 women, 12 75% of the 226 women achieving a further pregnancy had a successful outcome with survival beyond 24 weeks. Thus, when taking into account pregnancy losses occurring after 24 weeks, we assumed that women assigned to receive placebo would have 70% chance of a live and viable birth. On the basis of a minimal clinically important difference of 10 percentage points in live-birth rates, on enoxaparin, we needed to enroll 580 women for a power of 80%, with a two-tailed α of 0.05. We aimed to enroll 610 women, to account for potential lost to follow-up.
Study Monitoring
According to the study protocol, a data and safety monitoring board, 14 whose members were unaware of the study-group assignments, performed two planned blinded interim analyses, after 200 (~one third of the planned inclusions) and 400 women (~two thirds of the planned inclusions) were randomized. The first planned data and safety monitoring board meeting was held on September 4, 2012. The analysis included the data from 207 women in whom the primary outcome had occurred or in whom a miscarriage had occurred by June 1, 2012. On the basis of this analysis, the board advised discontinuation of the study because of futility.
The recruitment stopped on October 31, 2012. The study was discontinued on September 2, 2013 after the last woman completed the last visit planned in the protocol.
For
Results
Study population
Among 314 women assessed for eligibility, 258 were enrolled, with 138 assigned to the enoxaparin group, and 120 to the placebo group (Figure 1) . Two women immediately withdrew consent before the first injection. Thus the data of 256 women were analysed (138 and 118 women in enoxaparin and placebo groups, respectively). No woman was lost to follow-up yet some did not complete the treatment as planned in the protocol (Figure 1 ). Only one woman declined injections early after inclusion (3 weeks of injections). Five other patients preferred to stop injections after the first trimester of pregnancy because they were reassured regarding the risk of pregnancy loss and consequently less motivated for the selfinjections. The investigators decided to discontinue the injections in three women (always after the first trimester of pregnancy) because of suspected side effects: cervix bruising (n=1, placebo arm), skin reaction (n=1, enoxaparin arm), thrombocytopenia (n=1, enoxaparin arm).
Heparin-induced thrombocytopenia was ruled out in the latter two cases.
Baseline characteristics were similar between the study groups and are summarized in Table   1 . Mean age was 32 years (range: 18-44 years), 72% of them had three or more previous miscarriages. The mean gestational age at randomization (i.e. time at which the injections were started) was 39 days of amenorrhea.
Outcomes
Of the 256 women who were included in the intention-to-treat analysis, 178 (69.5%) had a live-birth. The live-birth rates were 66.6% and 72.9% for the enoxaparin and placebo group, respectively. The rates did not differ significantly between groups (absolute difference in livebirth rates -6% [95% CI −17.1 to 5.1; p=0.34]) ( Table 2 ). We did not observe any significant difference in secondary outcomes between the two groups ( Table 3) . During the study, 30.4% of women enrolled in the enoxaparin group, vs.
23.7% in the placebo group suffered another miscarriage (RR 1.28, 95% CI: 0.85 to 1.93).
Most of the losses (84.3 %) occurred before ten weeks' gestation.
Maternal adverse events are displayed in Table 3 . Seven women (4 in the enoxaparin arm, 3 in the placebo arm) developed thrombocytopenia, but none of them were diagnosed with heparin-induced thrombocytopenia. Two women in the enoxaparin group required blood transfusions after delivery whereas injections were discontinued for more than 10 days. One woman in the enoxaparin group displayed indurations at the injection sites leading to an interruption of the study intervention at 12 weeks' gestation. Within the two following weeks, she suffered an unexplained intrauterine fetal death. She had no heparin-induced thrombocytopenia (negative ELISA test), and no cause was found to explain the intrauterine death after placenta and foetus examination. Among the premature infants, one in each group died in intensive care unit.
There were no significant interactions between the study-group assignment and the number of previous miscarriages, the presence or absence of a previous live birth, the presence or absence of a previous loss after 10 weeks' gestation, age, or the strata of randomization (Figure 2 
Discussion
In this first reported randomized double-blind placebo-controlled trial, enoxaparin given at the daily dose of 40 mg did not improve the chance of a live birth in non-thrombophilic women with a history of unexplained recurrent miscarriage. Enoxaparin was safe during early pregnancy at the daily dose of 40 mg. Our trial was designed to detect a minimal clinically important difference of 10% in live-birth rates. The upper limit of the 95% confidence interval around the difference in rates of live-birth between groups excludes a 10% benefit with enoxaparin (absolute difference of -6% [95% CI -17.1 to 5.1]).
Since initiation of our study in 2006, the results of several randomized trials were reported in unexplained recurrent miscarriage. [15] [16] [17] [18] [19] [20] [21] [22] Only one was placebo-controlled, the ALIFE study, a randomized trial among all-comer women (around 85% had a negative thrombophilia workup) which amounted to a turning point: the lack of any beneficial effect of aspirin was clearly demonstrated. Additionally, the use of open-label LMWH in combination with aspirin, in a third intervention arm, did not show any improvement in live-birth rates versus oral placebo. 18 The SPIN study showed no efficacy of open-label LMWH plus aspirin versus intense pregnancy surveillance alone (all-comer women)
. 19 Yet, a detrimental effect of aspirin could not be ruled out and might explain the lack of efficacy of the combination with LMWH. 10, 18 As regards the use of LMWH alone, two randomized open-label but underpowered trials did not show a significant benefit of enoxaparin against aspirin, 15, 20 although in HABENOX, 20 the live-birth rate was higher with LMWH (71% vs. 61%, for enoxaparin and aspirin respectively, p: 0.45, all-comer women). Lastly, in a randomized single-blinded trial with some methodological limitations, live-birth rates were significantly higher among women who were assigned to receive enoxaparin than among those assigned to receive a not well-characterized oral placebo (81% vs. 48%); all had a negative hereditary thrombophilia work-up. 16 Thus, conclusive data were still lacking concerning the effect of LMWH alone in improving the
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outcome of pregnancy in women with unexplained recurrent miscarriage. This is supported by the last meta-analysis 23 in which the authors state that only the data of 6 patients 22 could be analyzed as regards the effect of heparin alone versus no treatment, when excluding studies at high risk of bias. 16, 17 The use of LMWH was supported by some studies, in which a basal prothrombotic state, outside of pregnancy, was measured, in women with previous recurrent miscarriage and without known thrombophilia. [24] [25] [26] Additionally, heparin and LMWH have other biological properties that could be critical for implantation and placentation. [27] [28] [29] [30] [31] [32] [33] [34] [35] It is possible, that to be beneficial, heparins may require to be given, at the time of the initial implantation. Our study was not designed to test such a hypothesis. The injections were most often initiated at 5-6
weeks' gestation, although the instruction was to begin the treatment at the earliest during pregnancy. In the per-protocol analysis taking into account the appropriate exposure to the assigned study drug (early and long enough), the rates of live-birth in each intervention group were similar (73.3%). Likewise, the subgroup analysis did not suggest any clinical benefit from enoxaparin for any subset of patients at higher risk of recurrence.
Some other limitations of our study warrant consideration. We initially planned to recruit 305 patients in each group. Nevertheless, physicians, often convinced of LMWH efficacy, were sometimes reluctant to include their patients in the trial, because of placebo injections.
As a result, the recruitment was slower than expected. On the basis of the review of the first planned blinded interim analysis, the steering committee decided to prematurely close the study. More than 5 additional years of recruitment would have been necessary to reach statistical significance and it turned out after unblinding treatment allocation, that this would have been to demonstrate superiority of placebo. Another limitation is that this trial did not assess enoxaparin in women with known inherited thrombophilias (factor V Leiden and Prothrombin G20210A mutations, Protein S, C and Antithrombin III deficiencies). No
For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From previous reported study was designed to robustly examine the sub-group of women with thrombophilia. Noteworthy, in a recently reported open-label trial (TIPPS), 35 among 69 thrombophilic women with previous recurrent miscarriage were randomized to receive antepartum LMWH without any impact on the live birth rate. 36 Lastly, we used a broad definition of recurrent miscarriage, more consistent with the current medical practice (i.e., two or more miscarriages). However, about 70% of our patients suffered 3 or more losses, as compared with 100%, 60% and 43% of the women enrolled in HABENOX, 20 ALIFE, 18 and SPIN, 19 respectively. Moreover, in our study, the live-birth rates were 66.6% and 72.9 % in enoxaparin and placebo groups, respectively (p: 0.34). These live-birth rates were consistent with those of the longitudinal study of Brigham et al 12 and of the HABENOX 20 and ALIFE 18 trials, suggesting similar disease severity. Noteworthy, the mean gestational age at miscarriage observed in our study, was similar to the one reported in ALIFE. 18 In conclusion, in this first reported randomized double-blind placebo-controlled trial, enoxaparin given at the daily dose of 40 mg did not improve the chance of a live birth in nonthrombophilic women with a history of unexplained recurrent miscarriage. Prophylactic doses of LMWH do not improve the chance of a live birth in non-thrombophilic women with unexplained recurrent miscarriage and should consequently no longer be routinely prescribed in this clinical setting. The women included in the per-protocol analysis were treated at least 7 days until loss or beyond 12 weeks'gestation AND the injections were started at or before 6 weeks' gestation or at least one week before the most advanced term reached before during previous pregnancies. Enoxaparin Placebo p Adverse events n Congenital abnormality*, n (%) Major bleeding, n (%) For personal use only. on August 31, 2017. by guest www.bloodjournal.org From
